Login | Register

Non-insulin Diabetes Drug Reaches Efficacy Goals, Lilly Reports

A non-insulin drug for diabetes decreased blood-sugar levels in four Phase 3 clinical trials, Boehringer Ingelheim GmbH and Eli Lilly & Co. (LLY), the developers of the treatment, announced Monday. The companies' diabetes partnership of two years was also altered, with Boehringer Ingelheim ending its involvement in the development of a different drug, an investigative form of insulin...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *